Research Area

Redoxis holds a portfolio of research projects for the treatment of chronic inflammatory and autoimmune diseases, linked together by a large unmet medical need and large patient populations or high-value niche therapy areas. Our projects target pathways identified by forward genetics with the aim of identifying and developing small molecule therapies.

Redoxis targets major inflammatory diseases such as Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and Inflammatory Bowel Disease (IBD).  In some instances, we target specialized niche indications, for example, peripheral nerve inflammatory conditions like Guillian-Barré syndrome (GBS), Chronic Granulomatous Disease (CGD) and inflammatory uveitis.

Redoxis closely collaborates with academic partners in Sweden, Europe and the U.S. to acquire or license novel projects within Redoxis’ research expertise.

Rheumatoid Arthritis (RA)

RA is a chronic, inflammatory, heterogeneous and disabling disease with a prevalence of 1%, mainly affecting peripheral joints. RA can lead to a substantial loss of joint function and mobility. Current treatments offer relief, at best, but no cure is available today.

Standard therapy for RA includes analgesia (painkillers), anti-inflammatory drugs and steroids that are used to suppress the symptoms; while disease-modifying antirheumatic drugs (DMARDs) are often required to reverse the disease progress and prevent long term damage. The development of so-called biologics has revolutionized the therapy of RA. Biologics are molecules that are produced by biologic processes, e.g. antibodies and cytokines. Unfortunately, these treatments are highly expensive, making their implementation as standard treatments impossible. Moreover, with a success rate of less than 50%, finding the right treatment for each individual patient is a lengthy process (approximately six months). One of the greatest challenges for biomedical research within the next several decades will be designing and delivering effective therapies that are tailored specifically to the genetic or biological state of an individual.

Multiple Sclerosis (MS)

MS is an autoimmune condition in which the immune system attacks the central nervous system (CNS). MS causes numerous physical and mental symptoms and often progresses to physical and cognitive disability. MS has a prevalence of about 0.1% in the population. Like RA, MS is a heterogenous disease and can take several forms. Symptoms can occur as discrete attacks (relapsing form) or slowly accumulate over time (progressive form). Most patients are initially diagnosed with relapsing-remitting MS but develop secondary-progressive MS over time. Between attacks, symptoms may disappear completely, but permanent neurological problems often persist, especially as the disease advances.

Treatments attempt to return function after an attack, prevent new attacks, and prevent disability. Biologic therapies have been beneficial in treating symptoms, but they can have adverse effects or be poorly tolerated. Furthermore, many patients pursue alternative treatments, despite the paucity of supporting scientific studies.